Bladder cancer trial explores immunotherapy cocktails to fight recurrence
NCT ID NCT03317158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1/2 trial tests the immunotherapy drug durvalumab alone or combined with other treatments (BCG, radiation, or chemotherapy) in 55 people with non-muscle invasive bladder cancer. The goal is to find safe doses and see if these combinations can eliminate cancer and prevent it from coming back. Participants have different histories with BCG treatment, including those who did not respond or relapsed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Durvalumab (Imfinzi) with or without BCG, radiation, gemcitabine, or docetaxel
What this could lead to
If successful, this could point toward new combination treatments for bladder cancer that reduce recurrence and delay or avoid bladder removal.
What could go wrong
This is an early phase 1/2 trial with only 55 participants, so results may not apply broadly. Some combinations may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BCG Oncology
TERMINATEDPhoenix, Arizona, 85032, United States
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
WITHDRAWNBoston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Indiana University Melvin and Bren Simon Cancer Center
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rush University Medical Cneter
WITHDRAWNChicago, Illinois, 60612, United States
-
Stanford University
WITHDRAWNStanford, California, 94305, United States
-
University of Iowa Hospitals and Clinics
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of North Carolina at Chapel Hill
ACTIVE_NOT_RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact